Quick Answer
Immunovant, Inc. reported Stockholders Equity of $707.45 million for fiscal year 2025.
Immunovant, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $707.45M | +14.5% |
| 2024 | $617.76M | +70.4% |
| 2023 | $362.49M | -22.8% |
| 2022 | $469.82M | +20.0% |
| 2021 | $391.48M | +316.2% |
| 2020 | $94.07M | +1181.8% |
| 2019 | $7.34M | +1885.6% |
| 2018 | -$411.0K | +72.5% |
| 2018 | -$1.50M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $986.13M | +179.7% | +89.7% |
| September 30, 2025 | $519.71M | +15.7% | -14.6% |
| June 30, 2025 | $608.54M | +11.7% | -14.0% |
| March 31, 2025 | $707.45M | +14.5% | +100.6% |
| December 31, 2024 | $352.62M | -48.1% | -21.5% |
| September 30, 2024 | $449.05M | +78.3% | -17.6% |
| June 30, 2024 | $544.66M | +81.6% | -11.8% |
| March 31, 2024 | $617.76M | +70.4% | -9.1% |
- Immunovant, Inc. showed an increase of +14.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Immunovant, Inc.’s stockholders equity has grown by 47357.6% (from -$1.50 million to $707.45 million).
- The most recent figure is from Immunovant, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: